Home Newsfeeds Oppenheimer Initiates Coverage On Rumble with Perform Rating

Oppenheimer Initiates Coverage On Rumble with Perform Rating

Oppenheimer analyst Jason Helfstein initiates coverage on Rumble (NASDAQ:RUM) with a Perform rating.

byBenzinga Newsdesk

December 2, 2022

1 minute read

Oppenheimer analyst Jason Helfstein initiates coverage on Rumble (NASDAQ:RUM) with a Perform rating.

Analyst Ratings

5 Analysts Have This to Say About Esperion Therapeutics

By Benzinga Insights

August 2, 2:00 PM

Esperion Therapeutics (NASDAQ:ESPR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

ESPR

Reported Late Wednesday, G1 Therapeutics Provides Initial Results From Phase 2 Mechanism Of Action Trial In Early-Stage Triple Negative Breast Cancer Show That A Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

By Benzinga Newsdesk

December 8, 3:13 AM

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor

GTHX

EPKINLY Approved By U.S. FDA As The First And Only Bispecific Antibody To Treat Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

By Benzinga Newsdesk

May 19, 12:37 PM

AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients

ABBV

Beeper Mini Gives Up On iMessage After Apple’s ‘Interference’, Makes Its Bridge Open Source

By Benzinga Neuro

December 22, 7:55 AM

Despite these setbacks, Beeper continues to assert that Beeper Mini is secure and upgrades unencrypted chats between iPhone and Android users to encrypted, blue bubble chats.

AAPL

Oppenheimer Initiates Coverage On Rumble with Perform Rating

Related Posts

5 Analysts Have This to Say About Esperion Therapeutics

Reported Late Wednesday, G1 Therapeutics Provides Initial Results From Phase 2 Mechanism Of Action Trial In Early-Stage Triple Negative Breast Cancer Show That A Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

EPKINLY Approved By U.S. FDA As The First And Only Bispecific Antibody To Treat Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Beeper Mini Gives Up On iMessage After Apple’s ‘Interference’, Makes Its Bridge Open Source